Total Funding
74
47
Total FundingSeries C raised
Growth Score
-16 pts
Heat Score
-13 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
26618
Abcuro develops immunotherapies to treat autoimmunity and cancer.
- George Eldridge: Chief Financial OfficerPast Role: Aerovate Therapeutics, Chief Financial Officer
Raquel Orozco: DirectorPast Role: Boehringer Ingelheim, Senior Bioprocess Engineer, Process Science
About the Company
Abcuro’s mission is to develop immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by their founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivo validation
in diseased tissue has uncovered new approaches to target key compartments of the immune system.
